Proarrhythmic effects of DL- and D-sotalol on the 'Border Zone' between normal and ischemic regions of isolated ventricular myocardium and antiarrhythmic effects on reperfusion

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 1, 1998, Pages 126-139

  Picard, Sandra ^a   Rouet, René ^a   Monti, Francesco ^b   Puddu, Paolo Emilio ^b   Ducouret, Pierre ^a   Flais, Frédéric ^a   Libersa, Christian ^c   Gérard, Jean Louis ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Arrhythmias; Class III drugs; Ischemia; Multivariate analysis; Reperfusion; Sotalol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL; SOTALOL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GUINEA PIG; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; MALE; MEMBRANE STEADY POTENTIAL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; FEMALE; GUINEA PIGS; HEART; HEART VENTRICLES; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIUM; SOTALOL;

EID: 0031984707     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199801000-00018     Document Type: Article

References (46)

1. Cobbe SM. Class III antiarrhythmics: put to the SWORD? Heart 1996;75:111-3.
2. Singh BN, Nademanee K. Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations. Am Heart J 1985;109:421-30.
3. Finance O, Manning A, Chatelain P. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol 1995;26:570-6.
4. Deedwania P. Suppressant effects of conventional beta-blockers and sotalol on complex and repetitive ventricular premature complexes. Am J Cardiol 1990;65(suppl):43-50A.
5. Lynch J, Wilber D, Montgomery D, Hsieh T, Patterson E, Lucchesi B. Antiarrhythmic and antifibrillatory actions of the levo and dextrorotatory isomers of sotalol. J Cardiovasc Pharmacol 1984; 6: 1132-41.
6. Roden DM. Usefulness of sotalol for life-threatening ventricular arrhythmias. Am J Cardiol 1993;72:51-55A.
7. Hohnloser SH, Zabel M, Krause T, Just H. Short- and long-term antiarrhythmic and hemodynamic effects of D,L-sotalol in patients with symptomatic ventricular arrhythmias. Am Heart J 1992; 123:1220-4.
8. Hohnloser S, Meinertz T, Stubbs P, et al. Efficacy and safety of D-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy: results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. Circulation 1995;92:1517-25.
9. Camm AJ, Paul V. Sotalol for paroxysmal supraventricular tachycardias. Am J Cardiol 1990;65(suppl):67-73A.
10. Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther 1985;232:817-25.
11. Varró A, Nakaya Y, Elharrar V, Surawicz B. Effect of antiarrhythmic drugs on the cycle length-dependent action potential duration in dog Purkinje and ventricular muscle fibers. J Cardiovasc Pharmacol 1986;8:178-85.
12. Ishii M, Kamiya J, Hashimoto K. Cellular electrophysiological effects of MS-551, a new class III antiarrhyhthmic agent. Drug Dev Res 1995;35:61-8.
13. Lathrop DA. Electro-mechanical characterization of racemic sotalol and its optical isomers on isolated canine ventricular trabecular muscles and Purkinje strands. Can J Physiol Pharmacol 1985; 63:1506-12.
14. Montera M, Schmitt C. Differential effects of D-sotalol on endocardial and epicardial action potentials of human ventricular myocardium in dilated cardiomyopathy. J Cardiovasc Pharmacol 1994;24:883-9.
15. McComb JM, McGovern B, McGowan JB, Ruskin JN, Garan H. Electrophysiologic effects of D-sotalol in humans. J Am Coll Cardiol 1987;10:211-7.
16. Antonaccio MJ, Gomoll AW. Sotalol - pharmacological and antiarrhythmic effects. Cardiovasc Drug Rev 1988;6:239-63.
17. Pasnani JS, Ferrier GR. Pro- and anti-arrhythmic effects of D-sotalol and DL-sotalol in an isolated tissue model of ischemia and reperfusion. J Pharmacol Exp Ther 1994;271:184-92.
18. Lipka L, Dizon J, Reiffel J. Desired mechanisms of drugs for ventricular arrhythmia: class III antiarrhythmic agents. Am Heart J 1995;130:632-40.
19. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-36.
20. Reisinger J, Shenasa M, Lubinski A, et al. Clinical implications of pleomorphic ventricular tachycardias on oral sotalol therapy. Eur Heart 1995;16:377-82.
21. Hondeghem L, Snyders D. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-90.
22. Claudel JP, Touboul P. Sotalol: From "just another beta blocker" to "the prototype of class III antidysrhythmic compound." Pacing Clin Electrophysiol 1995;18:451-67.
23. + channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity. J Cardiovasc Pharmacol 1995;26:847-54.
24. kr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. J Am Coll Cardiol 1995;25:1609-14.
25. Hofman H. Interaction between a normoxic and a hypoxic region of guinea pig and ferret papillary muscle. Circ Res 1985;56:876-83.
26. Janse MJ, Cinca J, Morena H, et al. The "border zone" in myocardial ischemia: an electrophysiological, metabolic and histochemical correlation in the pig heart. Circ Res 1979;44:576-88.
27. El-Sherif N, Mehra R, Gough WB, Zeiler RH. Ventricular activation patterns of spontaneous and induced ventricular rhythms in canine one-day-old myocardial infarctions: evidence for local and reentrant mechanisms. Circ Res 1981;51:152-66.
28. Hearse DJ, Yellon DM. The "border zone" in evolving myocardial infarction: controversy or confusion? Am J Cardiol 1981; 47:1321-34.
29. Schiariti M, Puddu PE, Rouet R. Multivariate prediction of spontaneous repetitive responses in ventricular myocardium exposed in vitro to simulated ischemic conditions. Int J Cardiol 1994;45:9-22.
30. Rouet R, Adamantidis M, Honore E, Dupuis B. In vitro abnormal repetitive responses in guinea pig ventricular myocardium exposed to combined hypoxia, hyperkalemia and acidosis. J Appl Cardiol 1989;4:19-29.
31. Puddu PE, Rouet R. Are different pharmacokinetic properties of lidocaine versus propafenone in normal as compared to ischemic myocardium responsible for different electrophysiologic effects which help preventing arrhythmias? [Editorial comment]. Cardiologia 1988;33:459-62.
32. Belichard P, Pruneau D, Rouet R, Salzmann JL. Electrophysiological responses of hypertrophied rat myocardium to combined hypoxia, hyperkalemia and acidosis. J Cardiovasc Pharmacol 1991;17(suppl 2):S141-5.
33. Morena H, Janse MJ, Fiolet JWT, Krieger WJG, Crijns H, Durrer D. Comparison of the effects of regional ischemia, hypoxia, hyperkalemia and acidosis on intracellular and extracellular potentials and metabolism in isolated porcine heart. Circ Res 1980;46:634-46.
34. Afifi AA, Clark V. Computed-aided multivariate analysis. 2nd ed. New York: Van Nostrand Reinhold, 1990:353-8.
35. Neuvonen PJ, Elonen E, Tanskanen A, Tuomilehto J. Sotalol prolongation of the QT-c interval in hypertensive patients. Clin Pharmacol Ther 1982;32:25-32.
36. Coetzee WA. ATP-sensitive potassium channels and myocardial ischemia: why do they open? Cardiovasc Drug Ther 1992;6:201-8.
37. Yuan S, Wohlfart B, Olsson SB, Blomström-Lundqvist C. The dispersion of repolarization in patients with ventricular tachycardia. Eur Heart J 1995;16:68-76.
38. Ferrier GR, Guyette CM. Ventricular tachycardia in an isolated guinea pig ventricular free wall model of ischemia and reperfusion. J Cardiovasc Pharmacol 1991;17:228-38.
39. Myers ML, Bolli R, Lekich RF, Hartley CJ, Roberts R. Enhancement of recovery of myocardial function by oxygen free-radical scavengers after reversible regional ischemia. Circulation 1985;72:915-21.
40. Tilton RG, Watts JA, Land MP, Larson KB, Sutera SP, Williamson JR. Discordant effects of nisoldipine on coronary vascular resistance and permeability changes during reflow after ischemia in isolated rabbit hearts. J Mol Cell Cardiol 1991;23:861-72.
41. Manning AS, Come R, Isted K, Coltart DJ, Hearse DJ. Reperfusion-induced ventricular fibrillation: modification by pharmacological agents. Adv Myocardiol 1985;6:515-28.
42. Duo GS, Hoff P, Kupersmith J. Repolarization interactions between cardiac segments of varying action potential duration. Am Heart J 1989;117:854-61.
43. Janse MJ, VanCapelle JL, Morsink H, et al. Flow of "injury" current and patterns of excitation during early ventricular arrhythmias in acute regional myocardial ischemia in isolated porcine and canine hearts: evidence for two different arrhythmogenic mechanisms. Circ Res 1980;47:151-65.
44. Kupersmith J, Li ZY, Maldonado C. Marked action potential prolongation as a source of injury current leading to border zone arrhythmogenesis. Am Heart J 1994;127:1543-53.
45. Corr PB, Witowski FX. Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion of ischemic myocardium. Circulation 1983;68:16-24.
46. Tzivoni D, Keren A, Granot H, Gottlieb S, Benhorin J, Stern S. Ventricular fibrillation caused by myocardial reperfusion in Prinzmetal angina. Am Heart J 1983;105:323-5.